Gain complete access to the report @ https://www.futuremarketinsights.com/reports/veterinary-respiratory-disease-treatment-market
Veterinary Respiratory Disease Market: Drivers and Restraints
The global market for veterinary respiratory disease market is driven due to increase in respiratory infections, lack of drugs to treat specific pathogens, to decrease the mortality rates of animals are driving the growth of veterinary respiratory disease market during the forecast period. In 2011, U.S Department of Agriculture’s National Animal Health Monitoring System (NAHMS) had conducted study to understand the treatment cost and incidence of respiratory diseases in cattle. The results showed that around 16.2 percent of cattle affected with respiratory diseases and treatment cost for cattle is the $23.60/per case. The cost for treating veterinary respiratory disease has increased significantly over the years. In the UK, cattle industry spends around 60 million euros annually to treat respiratory disease conditions. Veterinary respiratory disease is more commonly affected by the young calves and animals this due to improper development of immune system. The major restraints of the market are the cost of the drugs, government regulations to reduce the usage of antibiotics are hindering the growth of this market.
Veterinary Respiratory Disease Market: Overview
Cost effective, long-acting drugs would create attractive growth opportunities for the veterinary respiratory disease market over the forecast period. To treat respiratory diseases in cattle critically important, antibiotics like aminoglycosides, cephalosporins and penicillins are most commonly used followed by macrolides and fluoroquinolones. In the case of respiratory diseases in pigs, 47% of tetracyclines are used followed by pencillins (21%), macrolides (10%) and potentiated sulphonamides (8%). Rifampicin is commonly used to treat respiratory infections in horses. In the veterinary respiratory disease market antibiotics and vaccines occupies the significant share in the market and dominates during the forecast period. Based on distribution channel, veterinary pharmacies dominated the current market and expected to dominate during the forecast period. The number of e-commerce pharmacies is increasing due to increasing penetration of internet across the globe. Both parenteral and oral routes are most commonly used to treat the veterinary respiratory diseases.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2526
Veterinary Respiratory Disease Market: Regional Overview
Region-wise, the global veterinary respiratory disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America dominated the global market for veterinary respiratory disease owing to established health care and practiced veterinary practitioners are driving the growth of this market. Asia-Pacific is expected to surpass the European market during the forecast owing to increase in the cattle population.
Veterinary Respiratory Disease Market: Players
Some of the players in global veterinary respiratory disease market include Zoetis, Merck & Co., Inc., Eli Lilly Company, Virbac group, Bayer, Vetoquinol, Boehringer Ingelheim, Ceva and Bimeda animal health.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordiccountries, BENELUX)
- Eastern Europe (Russia, Poland, Rest of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle Eastand Africa (GCC, S. Africa, N. Africa, Rest Of MEA)
The report is a compilation of first-hand information, qualitative, and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2526
Veterinary respiratory disease market is segmented on the basis of drug classification, distribution channel, and end user.
Based on the drug classification, the veterinary respiratory disease market is segmented into the following:
- Antibiotics
- Penicillins
- Aminoglycosides
- Cephalosporins
- Others
- Antiparasitics
- NSAID’s
- Antiviral
- Vaccines
Based on the route of administration, the veterinary respiratory disease market is segmented into the following:
- Oral
- Parenteral
- Other
Based on the distribution channel, the veterinary respiratory disease market is segmented into the following:
- Veterinary Pharmacies
- Retail Pharmacies
- E-commerce
For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/2526
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
